Japan's MHLW/PMDA recommends package insert revisions

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2018年 / 1732卷 / 1期

关键词：

D O I：

10.1007/s40278-018-55457-x

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：1 / 1

相关论文

共 50 条

[1] PMDA recommends package insert revisions for five products
Reactions Weekly, 2020, 1826 (1) : 4 - 4
[2] Package insert revisions required: Japan's PMDA findings
Reactions Weekly, 2016, 1615 (1) : 4 - 4
[3] PMDA: package insert revisions needed for four drugs in Japan
Reactions Weekly, 2017, 1665 (1) : 1 - 1
[4] Package insert revisions recommended by PMDA
Reactions Weekly, 2019, 1783 (1) : 6 - 6
[5] Package insert revisions recommended by PMDA
Reactions Weekly, 2017, 1682 (1) : 5 - 5
[6] Recent package insert revisions recommended by PMDA
Reactions Weekly, 2018, 1696 (1) : 3 - 3
[7] PMDA: necessary package insert revisions from April 2018
Reactions Weekly, 2018, 1700 (1) : 1 - 1
[8] PMDA: Necessary Package Insert Revisions from April 2018
不详
PHARMACEUTICAL MEDICINE, 2018, 32 (04) : 299 - 299
[9] Package insert revisions for three therapies in Japan
Reactions Weekly, 2018, 1727 (1) : 3 - 3
[10] Package insert revisions for apremilast, ceftriaxone in Japan
Reactions Weekly, 2018, 1715 (1) : 2 - 2

← 1 2 3 4 5 →